Publication: Paclitaxel carboplatin in elderly patients with advanced non-small cell lung cancer
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Çubukcu, Erdem | |
dc.contributor.buuauthor | ÇUBUKÇU, ERDEM | |
dc.contributor.buuauthor | Aksoy, Savas | |
dc.contributor.buuauthor | Çubukcu, Sinem | |
dc.contributor.buuauthor | ÇUBUKÇU, SİNEM | |
dc.contributor.buuauthor | Canhoroz, Mustafa | |
dc.contributor.buuauthor | Karadağ, Oya | |
dc.contributor.buuauthor | Alkış, Nihan | |
dc.contributor.buuauthor | Manavoğlu, Osman | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı. | |
dc.date.accessioned | 2024-09-06T06:11:37Z | |
dc.date.available | 2024-09-06T06:11:37Z | |
dc.date.issued | 2012-07-01 | |
dc.description.abstract | Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non -small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages a70 years) who received PC for stage III (n=111 or IV (n=34) NSCLC were evaluated retrospectively. Results: There were 43 males and 2 females, with a median age of 75.5 (range, 70-62). The response rate was 40%. The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively. One-year survival rate was 51%. Treatment was well tolerated by the patients. The most frequent side effect observed was grade 3 or 4 neutropenia (57.795). There was no treatment related death. Discussion: PC regimen may be a good alternative for the treatment of elderly patients with advanced NSCLC. | |
dc.identifier.doi | 10.4328/JCAM.705 | |
dc.identifier.endpage | 295 | |
dc.identifier.issn | 1309-0720 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 293 | |
dc.identifier.uri | https://doi.org/10.4328/JCAM.705 | |
dc.identifier.uri | https://hdl.handle.net/11452/44359 | |
dc.identifier.volume | 3 | |
dc.identifier.wos | 000215547400012 | |
dc.indexed.wos | WOS.ESCI | |
dc.language.iso | en | |
dc.publisher | Derman Medical Publ | |
dc.relation.journal | Journal Of Clinical And Analytical Medicine | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Non-small cell | |
dc.subject | Lung | |
dc.subject | Elderly | |
dc.subject | Chemotherapy | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Medicine, general & internal | |
dc.subject | General & internal medicine | |
dc.title | Paclitaxel carboplatin in elderly patients with advanced non-small cell lung cancer | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | f971677f-09c5-4463-bf01-3c6341fbe5f7 | |
relation.isAuthorOfPublication | 375ef438-7ff8-4a42-97a4-74096fac117f | |
relation.isAuthorOfPublication.latestForDiscovery | f971677f-09c5-4463-bf01-3c6341fbe5f7 |